Liquidia Corporation

Home
Liquidia Corporation

Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease.

A biopharmaceutical company focused on the development & commercialization of products in pulmonary hypertension and other applications of its PRINT® Technology. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology.

10/06/2025

This week’s podcast sponsored by Liquidia in concert with leading patient advocacy group Phaware Global Association, features Dr. Rodolfo Estrada discussing the technology and clinical development behind YUTREPIA™ (treprostinil) inhalation powder.

Check out this Special Edition episode today by visiting https://bit.ly/43Abd1k.

27/05/2025

Earlier this month, Liquidia employees ventured from Morrisville to Durham in support of the North Carolina Biotechnology Center Triangle Women in STEM “2025 STEM Day @ Duke University.”

Liquidia was a proud sponsor of this year’s event, which provided a fun-filled day of educational and engaging STEM activities for 250+ students and their parents/guardians. In addition, several of our colleagues volunteered their free time to help facilitate the event and lead STEM-based workshops focused on biotechnology, artificial intelligence and music technology.

Thanks to all who helped make this enriching event a reality!

23/05/2025

Liquidia is proud to announce that the U.S. FDA has approved YUTREPIA™ (treprostinil) inhalation powder for patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Dr. Roger Jeffs, Chief Executive Officer of Liquidia, said: “Today, we celebrate for the patients and physicians who will now have access to a potential best-in-class dry-powder form of treprostinil with exceptional portability, tolerability, titratability and durability. Thank you to the clinical investigation team, our steering committee, and the members of the pulmonary hypertension patient communities who helped make this day a reality. With today’s milestone, our commercial team is prepared to launch YUTREPIA and bring meaningful change to the lives of patients in need, and we look forward to speaking with physicians and patients about the unique benefits of YUTREPIA in the days and weeks ahead.”

Please see today’s press release announcing YUTREPIA’s FDA approval here: https://bit.ly/3SiSAbJ

19/05/2025

During Liquidia's World PH Day celebration, the team raised funds to help fuel research and critical patient support services that benefit the pulmonary hypertension community.

Thanks go out to our compassionate and committed colleagues for consistently helping to make a positive impact in the lives of patients.

Here’s to making a difference together!

13/05/2025

This week’s podcast sponsored by Liquidia in concert with leading patient advocacy group Phaware Global Association, features Liquidia Medical Science Liaison, Seth Hall, MBA, RRT.

During this podcast, Seth takes listeners on a journey through the past, present, and future of inhaled therapies sharing how these treatments have evolved over time.

Check out this new episode today by visiting https://bit.ly/3YCMxCv.

28/03/2025

Liquidia Corporation (NASDAQ: LQDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) resubmission for YUTREPIA™ (treprostinil) inhalation powder to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The FDA confirmed that the resubmission was a complete, Class 1 response to the previous action letter issued on August 16, 2024, which granted tentative approval of YUTREPIA for both PAH and PH-ILD.

The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of May 24, 2025.

Dr. Roger Jeffs, Ph.D., Chief Executive Officer of Liquidia, said: “We are pleased that the FDA has responded promptly to the resubmission that we filed on Monday. We look forward to working with the FDA over the coming months as we seek final approval for YUTREPIA and, in the meantime, will continue preparations to support a launch of YUTREPIA as soon as possible.”

To see today’s press release, visit https://bit.ly/4l3mkGR

24/03/2025

Dr. Vani Ravichandran, Ph.D., a Liquidia Medical Science Liaison (MSL), recently participated in a Career Day panel at the University of Michigan where she spoke with cellular & molecular biology (CMB) doctoral students who are considering career paths outside of academia.

According to Vani, “The Ph.D. training provides students with skills that are highly transferable outside of academia. A career as an MSL enables one to have a real-world impact by bridging the gap between the bench and the bedside in various diseases, while honoring the inquisitiveness that often drives students to graduate school.”

When asked why she’s passionate about her role as an MSL, Vani replied, “I get to nerd out for a living – turning science into solutions. My role as an MSL lets me remain a lifelong learner, while using my rigorous scientific training to help improve patient care.”

Thank you, Vani, for inspiring students who may soon be part of our dynamic industry!

To learn more about Liquidia and the career opportunities currently available at the company, please visit us online at https://bit.ly/4aImI8O.

14/03/2025

Liquidia’s Ahmed Radwan, Senior Manager of Manufacturing Operations, has always leaned toward providing services that benefit our community. That’s why, when given the chance to inspire the next generation of female STEM leaders at the inaugural Athena Women in STEM Girls Conference at Meredith College – a one-day event designed for high school girls in the NC Triangle area – he jumped at chance to give back.

“ATHENA’s mission felt like a natural extension of my early work as the co-lead of Pfizer Women’s Resource Group, which involved creating mentorship opportunities where women could learn from other female leaders in the company to help them advance their careers. Partnering with the Athena Girls Conference was an easy decision since it aligned perfectly with my earlier work as an ally to women in STEM.”

Ahmed participated in the event by serving on a panel called “A Journey in STEM” with other Triangle-Area STEM professionals. “Watching the conference attendees light up with curiosity and confidence was an unforgettable moment. It was a powerful reminder of how life-changing this work truly is.”

Here’s to supporting the next wave of female leaders in STEM!

06/03/2025

We’re proud to introduce you to the new Liquidia.com...

While our brand may have evolved, we remain steadfast in our commitment to developing best-in-class therapies for rare cardiopulmonary diseases like pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) with the goal of helping patients breathe easier and live longer.

To learn more about how we are shaping the future of inhaled therapies, visit us online at https://bit.ly/49sB6Bs.

28/02/2025

Today on Rare Disease Day, we stand with the more than 300 million people worldwide who are living with a rare disease, and the countless caregivers, physicians, nurses and advocacy groups who together make our community so magnificently resilient.

26/02/2025

This February, Liquidia sponsored and participated in the Pulmonary Hypertension Association O2breath Walk and 5k in Tampa, Florida.

The event, which is designed to unite members of the pulmonary hypertension community to connect, celebrate the community's accomplishments and raise funds, helps support the organization’s ongoing programs and services.

Here’s to making a difference together!

10/02/2025

Did you know pulmonary arterial hypertension (PAH) and pulmonary arterial hypertension associated with interstitial lung disease (PH-ILD), two rare cardiopulmonary diseases, directly impact the heart’s ability to properly function?

Both PAH and PH-ILD lead to elevated blood pressure in the pulmonary arteries, resulting in heart and lung damage and a decreased lifespan for patients.

At Liquidia, we are committed to helping patients with and live longer and breathe easier. To learn more, visit https://bit.ly/4aImI8O.

Address

Website

https://www.liquidia.com/

Alerts

Be the first to know and let us send you an email when Liquidia Corporation posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Liquidia Corporation:

Shortcuts

Want your practice to be the top-listed Clinic?

Country:

City: